EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Association Between β‐Adrenoreceptor Agonists and Antagonists and Parkinson's Disease: Systematic Review and Meta‐Analysis

Agnieszka Szmigiel iD, Miguel Monteiro da Rocha, Kate Browne, Daniel Morales, David Benee Olsen, Charlotte Warren-Gash, Ian Douglas, Krishnan Bhaskaran, Helena Carreira iD

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70140 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Agnieszka Szmigiel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacovigilance Office, European Medicines Agency, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Adrenergic beta-Agonists, Adrenergic beta-Antagonists, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Funding: No specific funding was received for this study. Professor Bhaskaran is funded by a Wellcome Senior Research Fellowship (grant number 220283/Z/20/Z).….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background β‐agonists and β‐antagonists are among the most prescribed drugs worldwide. In 2018, studies suggesting a harmful association between propranolol and Parkinson's disease (PD) prompted a signal procedure by the European Medicines Agency's safety committee, which concluded with no update of product information. Several studies have been published since then. We aimed to systematically review, critically appraise, and meta‐analyse all studies on the association between the use of β‐antagonists (including propranolol) and β‐agonists, and the risk of PD.

Methods

We searched Embase and Medline up to December 2024 for observational and intervention studies that reported relative risk estimates of the association between use of these medicines and PD. Two reviewers screened the records, extracted the data, and assessed the risk of bias. The restricted maximum likelihood method was used to compute pooled effect estimates and 95% confidence intervals (CIs).

Results

Twenty‐two studies were eligible. Overall, 20 had a high risk of bias in at least one domain. Twelve studies had medium to high risk of outcome misclassification. Of the 14 studies concerning β‐antagonists, eleven had an unclear or high risk of protopathic bias, as propranolol is indicated for the treatment of essential tremor. Control for confounding by socio‐economic status, area of residence (urban/rural), and smoking (a protective factor against PD) was deficient or lacking in 9/22, 15/22, and 12/22 studies, respectively. Lag times were applied in 9/22 studies. In meta‐analysis, the summary relative risk (RR) of PD was 1.41 (95% CI: 1.18–1.68) for the class of β‐antagonists (12 studies) and 0.93 (0.84–1.03) for β2‐agonists (11 studies). Among specific β‐antagonists, the summary RR of PD was 2.36 (1.66–3.36) for propranolol (7 studies), 0.84 (0.80–0.88) for carvedilol (3 studies) and 1.02 (0.87–1.18) for metoprolol (4 studies). For specific β2‐agonists, summary RR was 0.88 (0.77–1.01) for salbutamol (7 studies), 0.91 (0.88–0.95) for short‐acting β2‐agonists (6 studies), and 0.85 (0.76–0.96) for long‐acting β2 agonists (5 studies). Restricting to subgroups based on quality criteria resulted in weaker or non‐statistically significant associations.

Conclusion

The quality and quantity of the available evidence do not support a causal association between use of β‐adrenoreceptor modulators and PD. Significant associations are most likely explained by protopathic bias and confounding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-AgonistsAdrenergic beta-AntagonistsParkinson DiseaseHumansPropranolol

Stichwörter der Autor:innen

Parkinson's diseaseadrenergic beta‐agonistsadrenergic beta‐antagonistssystematic review

Substanzen

Adrenergic beta-AgonistsAdrenergic beta-AntagonistsPropranolol

Autor:innen und Institutionen

  • Pharmacovigilance Office, European Medicines Agency, Amsterdam, the Netherlands.
  • Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
  • North Region Health Administration, National Health Service, Lisbon, Portugal.
  • Medical and Health Information Service, European Medicines Agency, Amsterdam, the Netherlands.
  • Real World Evidence, European Medicines Agency, Amsterdam, the Netherlands.
  • Department of Pharmacovigilance, Norwegian Medical Products Agency, Oslo, Norway.

ORCID-Profile: Agnieszka Szmigiel, Helena Carreira

Förderung

  • Wellcome Trust
  • Funding: No specific funding was received for this study. Professor Bhaskaran is funded by a Wellcome Senior Research Fellowship (grant number 220283/Z/20/Z).…

Zitieren

APA

Szmigiel, A., da Rocha, M. M., Browne, K., Morales, D., Olsen, D. B., Warren-Gash, C., Douglas, I., Bhaskaran, K., & Carreira, H. (2025). Association Between β‐Adrenoreceptor Agonists and Antagonists and Parkinson's Disease: Systematic Review and Meta‐Analysis. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70140

Vancouver

Szmigiel A, da Rocha MM, Browne K, Morales D, Olsen DB, Warren-Gash C, et al. Association Between β‐Adrenoreceptor Agonists and Antagonists and Parkinson's Disease: Systematic Review and Meta‐Analysis. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70140

BibTeX
@article{Szmigiel2025,
  author = {Szmigiel, Agnieszka and da Rocha, Miguel Monteiro and Browne, Kate and Morales, Daniel and Olsen, David Benee and Warren-Gash, Charlotte and Douglas, Ian and Bhaskaran, Krishnan and Carreira, Helena},
  title = {Association Between β‐Adrenoreceptor Agonists and Antagonists and Parkinson's Disease: Systematic Review and Meta‐Analysis},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70140}
}
Kostenlos starten →